导向综合治疗对肝癌耐药基因表达的影响  被引量:3

EXPRESSION OF MULTIDRUG RESISTANCE GENE AFTER MULTIMODALITY TARGETING TREATMENT OF HEPATOCELLULAR CARCINOMA

在线阅读下载全文

作  者:汤文英[1] 汤钊猷[1] 刘康达[1] 邹合强[1] 鲍卫华[1] 

机构地区:[1]上海医科大学肝癌研究所

出  处:《上海医科大学学报》1995年第2期135-137,共3页Journal of Fudan University(Medical Science)

基  金:中山医院中青年研究基金资助

摘  要:用ABC免疫组织化学方法(简称组化)对92例肝细胞肝癌(HCC)标本进行了耐 药基因产物 P-GP的检测。结果:术前未治疗的 76例 HCC中,癌与癌周肝 P-GP组化染色 阳性率分别为60.5%(46/76)与69.7%(53/76);由导向综合治疗后切除的16例标本中其癌 与癌周肝分别为31.2%(5/16)与78.3%(11/15)。表明经导向综合治疗后HCC中P-GP的 表达显著低于来治疗组(P<0.05)。提示导向综合治疗有助于克服HCC耐药。A total of 96 specimens of hepatocellular carcinoma (HCC) and its surrounding liver tissues were studied to assess the expression multidrug resistance (mdr) gene product P-glycoprotein (P-GP) in HCC. P-GP was evaluated by an immunopexoxidase detection system. Results: In 76 untreated cases, P-GP was detected in 60.5%(46/76) of HCC, and in 69.7%(53/76) of surrounding liver tissues. In multimodality targeting treatment group (n= 16), expression of P-GP was observed in only 31.2%(5/16) of HCC and in 73.3%(11/15) of surrounding liver tissues. Expresaion of P-CP in multimodality targeting treatment group statistically lower then thet of untreated group (P<0.05). The results indicate that by multimodality targeting treatment, such as radioimmunotherapy, might change multidrug resistance of HCC.

关 键 词:抗药基因 P-GP 导向综合治疗 肝肿瘤  

分 类 号:R735.705[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象